在 #UnionConf2026 公布的 PARADIGM4TB(UNITE4TB-01)2期随机试验中,研究者评估了10种含 ganfeborole、BTZ-043 或两者联用的四药方案,受试者为利福平敏感肺结核患者。其中两种方案显示出值得进一步研究的前景。NEJM 主编 Eric J. Rubin 就此发表社论《Slightly Alive — Improving Antituberculosis Therapy》。
PARADIGM4TB 试验比较了含 ganfeborole 或 BTZ-043 的多种四药方案,为耐利福平敏感肺结核的联合治疗提供早期筛选依据。
Presented at #UnionConf2026:
In a phase 2 randomized trial, 10 new four-drug regimens that included ganfeborole, BTZ-043, or both were assessed in participants with rifampin-susceptible pulmonary tuberculosis. Two regimens showed promise for further study. Full PARADIGM4TB (UNITE4TB-01) trial results: https://nej.md/4C0qcke
Editorial by NEJM Editor-in-Chief Eric J. Rubin, MD, PhD: Slightly Alive — Improving Antituberculosis Therapy https://nej.md/4iKPfQR
@UnionConference
来源:NEJM · x.com